The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Positive cerebrospinal fluid (CSF) biomarkers of tau and amyloid beta42 suggest possible active underlying Alzheimer’s Disease (AD) including neurometabolic dysfunction and neurodegeneration leading to eventual cognitive decline. But the temporal relationship between CSF, imaging markers of neural function, and cognition has not been described. Using a statistical mediation model, we examined relationships between cerebrospinal fluid (CSF) analytes (hyperphosphorylated tau (p-Tau181p), β-amyloid 1–42 (Aβ1–42), total tau (t-Tau), and their ratios); change in cognitive function; and change in [18F]fluorodeoxyglucose (FDG) uptake using positron emission tomography (PET). We hypothesized that a) abnormal CSF protein values at baseline, result in cognitive declines by decreasing neuronal glucose metabolism across time, and b) the role of altered glucose metabolism in the assumed causal chain varies by brain region and the nature of CSF protein alteration. Data from 412 individuals participating in Alzheimer’s Disease Neuroimaging (ADNI) cohort studies were included in analyses. At baseline, individuals were cognitively normal (N = 82), or impaired: 241 with mild cognitive impairment, and 89 with Alzheimer’s disease. A parallel-process latent growth curve model was used to test mediational effects of changes in regional FDG-PET uptake over time in relation to baseline CSF biomarkers and changes in cognition, measured with the 13-item Alzheimer Disease’s Assessment Scale–cognitive subscale (ADAS-Cog). Findings suggested a causal sequence of events; specifically, FDG hypometabolism acted as a mediator between antecedent CSF biomarker alterations and subsequent cognitive impairment. Higher baseline concentrations of t-Tau, and p-Tau181p were more predictive of decline in cerebral glucose metabolism than lower baseline concentrations of Aβ1–42. FDG-PET changes appeared to mediate t-Tau or t-Tau/Aβ1–42 -associated cognitive change across all brain regions examined. Significant direct effects of alterations in Aβ1–42 levels on hypometabolism were observed in a single brain region: middle/inferior temporal gyrus. Results support a temporal framework model in which reduced CSF amyloid-related biomarkers occur earlier in the pathogenic pathway, ultimately leading to detrimental cognitive effects. Also consistent with this temporal framework model, baseline markers of neurofibrillary degeneration predicted changes in brain glucose metabolism in turn causing longitudinal cognitive changes, suggesting that tau-related burden precedes neurometabolic dysfunction. While intriguing, the hypothesized mediational relationships require further validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
A general approach to causal mediation analysis.
Imai, K., Keele, L., & Tingley, D. (2010) · Psychological Methods · doi:10.1037/a0020761 · Cited by 4,143
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 2×
“…adults (Craig-Schapiro et al., 2010; Fagan et al., 2007; Li et al., 2007; Roe et al., 2013), conversion from mild cognitive impairment (MCI) to AD (Hansson et al., 2006), and faster progression of functional and cognitive deficits in individuals with incipient dementia of the Alzheimer type…”
A practical and theoretical guide to measurement invariance in aging research
Horn, J. L., & Mcardle, J. J. (1992) · Experimental Aging Research · doi:10.1080/03610739208253916 · Cited by 1,592 · cited 1×
“To insure unambiguous interpretation of changes in the ADAS–Cog-13 between time points, we conducted longitudinal measurement invariance tests over a 36-month interval to determine whether the test items assessed the same attribute across time (Horn and McArdle, 1992; Meredith, 1993).”
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 2×
“Previous research (Reiman et al., 2001, 1996; Small et al., 2000) has demonstrated a link between ApoE ε4 carriers and lower cerebral glucose metabolism as compared to ApoE ε4 non-carriers.”
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 2×
“…p-Tau181p/Aβ1–42 and/or t-Tau/Aβ1–42 predict cognitive impairment within a few years of onset in non-demented older adults (Craig-Schapiro et al., 2010; Fagan et al., 2007; Li et al., 2007; Roe et al., 2013), conversion from mild cognitive impairment (MCI) to AD (Hansson et al., 2006), and faster…”
Mediation Models for Longitudinal Data in Developmental Research
Selig, J. P., & Preacher, K. J. (2009) · Research in Human Development · doi:10.1080/15427600902911247 · Cited by 804
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790 · cited 1×
“Previous research (Reiman et al., 2001, 1996; Small et al., 2000) has demonstrated a link between ApoE ε4 carriers and lower cerebral glucose metabolism as compared to ApoE ε4 non-carriers.”
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750
Self-citationde Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., Tsui, W., Kandil, E., Scherer, A. J., Roche, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191044198 · Cited by 629 · cited 1×
“…even at the preclinical asymptomatic stage of AD, which strongly suggests its suitability as amarker to study the effect of disease pathology on brain metabolic function (de Leon et al., 2001; Drzezga et al., 2011; Jagust et al., 2006; Mosconi et al., 2013, 2010, 2009; Reiman et al., 2001).”
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616 · cited 3×
“…fluid (CSF) and regional cerebral glucose metabolic rate, measured by positron emission tomography (PET) imaging with [18F]fluorodeoxyglucose uptake (FDG-PET), to predict outcomes, discriminate between disease stages, and assess prognosis (Choo et al., 2013; Herholz, 2003; Landau et al., 2010).”
Self-citation[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · cited 1×
“Tau imaging with PET (Chien et al., 2014; Okamura et al., 2014; Xia et al., 2013) is a new technique that can be done serially over time in individual patients.”
McArdle, J. J., Ferrer-Caja, E., Hamagami, F., & Woodcock, R. W. (2002) · Developmental Psychology · doi:10.1037/0012-1649.38.1.115 · Cited by 544
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541 · cited 1×
“Several ongoing projects are studying this phase and the application of the types of models we have described here to establish and test competing causality hypotheseswould be of interest in that phase of the disease (Johnson et al., 2014; Reiman et al., 2012; Villemagne et al., 2013).”
Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504 · cited 2×
“…example, elevated ratios of p-Tau181p/Aβ1–42 and/or t-Tau/Aβ1–42 predict cognitive impairment within a few years of onset in non-demented older adults (Craig-Schapiro et al., 2010; Fagan et al., 2007; Li et al., 2007; Roe et al., 2013), conversion from mild cognitive impairment (MCI) to AD…”
Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., Pirraglia, E., De Santi, S., Reisberg, B., Wisniewski, T., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1039-z · Cited by 487
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467 · cited 4×
“Similarly, in group studies FDG-PET has been consistently shown to be sensitive in detecting neurometabolic dysfunction even at the preclinical asymptomatic stage of AD, which strongly suggests its suitability as amarker to study the effect of disease pathology on brain metabolic function (de Leon et al., 2001; Drzezg…”
InfluentialRelationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 1×
“Detailed procedures for the FDG-ROI generation and subsequent smoothing and normalization of volumes are explained elsewhere (Jagust et al., 2010, 2009; Landau et al., 2010).”
Self-citationDissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387 · cited 1×
“In a recent study of brain banked cases, Perez-Nievas et al. (2013) showed that compared to AD, cognitively normal but amyloid harboring control brains were more likely to have diffuse rather than neuritic plaques, less inflammation and microglial activation, fewer neurofibrillary tangles, and more…”
A data-driven model of biomarker changes in sporadic Alzheimer’s disease
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308
Reducing between scanner differences in multi-center PET studies
Joshi, A., Koeppe, R. A., & Fessler, J. A. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.057 · Cited by 247 · cited 1×
“Further details on the quality control analyses and procedures to enhance uniformity and reduce variability in PET images across centers are provided in Joshi et al. (2009).”
Mosconi, L., De Santi, S., Brys, M., Tsui, W. H., Pirraglia, E., Glodzik-Sobanska, L., Rich, K. E., Switalski, R., Mehta, P. D., Pratico, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.030 · Cited by 238
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222
Brain imaging evidence of preclinical Alzheimer's disease in normal aging
Jagust, W., Gitcho, A., Sun, F., Kuczynski, B., Mungas, D., & Haan, M. (2006) · Annals of Neurology · doi:10.1002/ana.20799 · Cited by 222 · cited 2×
“Similarly, in group studies FDG-PET has been consistently shown to be sensitive in detecting neurometabolic dysfunction even at the preclinical asymptomatic stage of AD, which strongly suggests its suitability as amarker to study the effect of disease pathology on brain metabolic function (de Leon et al., 2001; Drzezg…”
Self-citationAmyloid burden and neural function in people at risk for Alzheimer's Disease
Johnson, S. C., Christian, B. T., Okonkwo, O. C., Oh, J. M., Harding, S., Xu, G., Hillmer, A. T., Wooten, D. W., Murali, D., Barnhart, T. E., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.028 · Cited by 218
Self-citationWhole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study
Sluimer, J. D., Bouwman, F. H., Vrenken, H., Blankenstein, M. A., Barkhof, F., van der Flier, W. M., & Scheltens, P. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.016 · Cited by 106
Wouters, H., van Gool, W. A., Schmand, B., Zwinderman, A. H., & Lindeboom, R. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2402 · Cited by 43
Cited by
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
Bejanin, A., Schonhaut, D. R., La Joie, R., Kramer, J. H., Baker, S. L., Sosa, N., Ayakta, N., Cantwell, A., Janabi, M., Lauriola, M., et al. (2017) · Brain · doi:10.1093/brain/awx243 · Cited by 778
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 315
Self-citationBrain fluorodeoxyglucose (FDG) PET in dementia
Kato, T., Inui, Y., Nakamura, A., & Ito, K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.003 · Cited by 236
Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline
Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., Bark, J. S., Cosio, D. M., LaPoint, M., Chhatwal, J. P., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24910 · Cited by 140
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133
“Published by Elsevier Inc. on behalf of the Alzh ns.org/licenses/by/4.0/). glucose metabolism assessed using fluorodeoxyglucose (FDG) PET [4], and increases in CSF proteins that may reflect damage, for example, Tau and neurofilament light (Nfl) [5,6].”
BackgroundInfluential
Metadata
- Authors
- Dowling, N. M., Johnson, S. C., Gleason, C. E., & Jagust, W. J.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 105
- Pages
- 357-368
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2055197036
- Cited by
- 43
- References
- 30
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.